NA
ONC

Neuburgh Advisers’s BeOne Medicines Ltd ONC Stock Holding History

Neuburgh Advisers’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$27K Hold
224
– – ﹤0.01% 869
2019
Q2 		$28K Buy
224
+32
+17% +$4.06K ﹤0.01% 879
2019
Q1 		$25K Hold
192
– – ﹤0.01% 877
2018
Q4 		$27K Buy
+192
New +$25.5K ﹤0.01% 851

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return

Neuburgh Advisers's ONC Position: Q3 2019 in Review

Neuburgh Advisers held its BeOne Medicines Ltd (ONC) position steady in Q3 2019 at 224 shares worth $27K. The position accounts for ﹤0.01% of the portfolio, ranked #869.

Neuburgh Advisers first reported a position in ONC in Q4 2018 and has held it in 4 quarters since. The position peaked at $28K in Q2 2019. 196 funds tracked by Wall St. Rank hold ONC as of Q3 2019.

  • Neuburgh Advisers held 224 shares of BeOne Medicines Ltd worth $27K as of Q3 2019.
  • Neuburgh Advisers left its BeOne Medicines Ltd share count unchanged in Q3 2019.
  • BeOne Medicines Ltd made up ﹤0.01% of Neuburgh Advisers's portfolio in Q3 2019, its #869 holding.
  • Neuburgh Advisers first reported a position in BeOne Medicines Ltd in Q4 2018 and has held it in 4 quarters since.
  • Neuburgh Advisers's BeOne Medicines Ltd position peaked at $28K in Q2 2019.
  • 196 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.